Ascorbic acid/menadione

Drug Profile

Ascorbic acid/menadione

Alternative Names: Apatone; Apatone-B

Latest Information Update: 07 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Summa Health System
  • Developer IC-MedTech; Summa Health System
  • Class Antineoplastics; Naphthoquinones; Small molecules; Vitamins
  • Mechanism of Action Antioxidants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bladder cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Joint disorders
  • Phase I/II Prostate cancer
  • No development reported Polycystic kidney disease
  • Discontinued Wounds

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Polycystic-kidney-disease in USA (PO)
  • 28 Jan 2016 Ascorbic acid/menadione is available for licensing -http://www.ic-medtech.com/partnerships_licensing.html
  • 10 Aug 2015 Development of ascorbic acid/menadione is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top